RxDoctor Payments Data

Alexis Pedersen, PA

Medical · Phoenix, AZNPI 1306425970

Payments from drug & device makers

$4,326in general payments, 2019–2025

Across 158 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$582
  • Sumitomo Pharma America, Inc.$483
  • Progenics Pharmaceuticals, Inc.$459
  • Dendreon Pharmaceuticals LLC$290
  • Myriad Genetic Laboratories, Inc.$259
  • Medtronic$245
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,29099%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,326 in reported general payments places this provider in the 80th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$144,728
Medicare patients
447
Services billed
8,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide30$427,360
ErleadaApalutamide17$229,406
MyrbetriqMirabegron102$99,893
GemtesaVibegron36$37,192
OrgovyxRelugolix11$27,866
Tamsulosin Hcl304$4,439
Testosterone40$4,268
Potassium Citrate ErPotassium Citrate20$2,952
Fesoterodine Fumarate ErFesoterodine Fumarate29$2,406
Methenamine Hippurate15$1,712
Finasteride109$1,570
Testosterone Cypionate49$1,439
Estradiol19$1,365
Solifenacin Succinate27$1,226
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst40$1,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$22$527,253132 claims
Johnson & JohnsonErleada$154$229,40617 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$483$65,05747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 748 medical providers in Arizona.

Other medical in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →